S&P 500   3,856.00 (-1.77%)
DOW   31,577.88 (-1.20%)
QQQ   316.59 (-2.33%)
AAPL   122.92 (-1.94%)
MSFT   231.74 (-1.20%)
FB   258.52 (-2.19%)
GOOGL   2,034.48 (-2.37%)
AMZN   3,095.00 (-2.04%)
TSLA   700.42 (-5.61%)
NVDA   538.95 (-7.07%)
BABA   244.52 (-2.32%)
CGC   34.04 (-4.38%)
GE   12.88 (-1.83%)
MU   90.49 (-2.19%)
NIO   47.98 (-7.48%)
AMD   83.45 (-4.01%)
T   28.77 (-2.08%)
F   11.92 (-2.85%)
ACB   11.12 (-4.47%)
DIS   193.88 (-1.84%)
BA   220.73 (-3.75%)
NFLX   542.59 (-1.96%)
BAC   36.23 (-0.41%)
S&P 500   3,856.00 (-1.77%)
DOW   31,577.88 (-1.20%)
QQQ   316.59 (-2.33%)
AAPL   122.92 (-1.94%)
MSFT   231.74 (-1.20%)
FB   258.52 (-2.19%)
GOOGL   2,034.48 (-2.37%)
AMZN   3,095.00 (-2.04%)
TSLA   700.42 (-5.61%)
NVDA   538.95 (-7.07%)
BABA   244.52 (-2.32%)
CGC   34.04 (-4.38%)
GE   12.88 (-1.83%)
MU   90.49 (-2.19%)
NIO   47.98 (-7.48%)
AMD   83.45 (-4.01%)
T   28.77 (-2.08%)
F   11.92 (-2.85%)
ACB   11.12 (-4.47%)
DIS   193.88 (-1.84%)
BA   220.73 (-3.75%)
NFLX   542.59 (-1.96%)
BAC   36.23 (-0.41%)
S&P 500   3,856.00 (-1.77%)
DOW   31,577.88 (-1.20%)
QQQ   316.59 (-2.33%)
AAPL   122.92 (-1.94%)
MSFT   231.74 (-1.20%)
FB   258.52 (-2.19%)
GOOGL   2,034.48 (-2.37%)
AMZN   3,095.00 (-2.04%)
TSLA   700.42 (-5.61%)
NVDA   538.95 (-7.07%)
BABA   244.52 (-2.32%)
CGC   34.04 (-4.38%)
GE   12.88 (-1.83%)
MU   90.49 (-2.19%)
NIO   47.98 (-7.48%)
AMD   83.45 (-4.01%)
T   28.77 (-2.08%)
F   11.92 (-2.85%)
ACB   11.12 (-4.47%)
DIS   193.88 (-1.84%)
BA   220.73 (-3.75%)
NFLX   542.59 (-1.96%)
BAC   36.23 (-0.41%)
S&P 500   3,856.00 (-1.77%)
DOW   31,577.88 (-1.20%)
QQQ   316.59 (-2.33%)
AAPL   122.92 (-1.94%)
MSFT   231.74 (-1.20%)
FB   258.52 (-2.19%)
GOOGL   2,034.48 (-2.37%)
AMZN   3,095.00 (-2.04%)
TSLA   700.42 (-5.61%)
NVDA   538.95 (-7.07%)
BABA   244.52 (-2.32%)
CGC   34.04 (-4.38%)
GE   12.88 (-1.83%)
MU   90.49 (-2.19%)
NIO   47.98 (-7.48%)
AMD   83.45 (-4.01%)
T   28.77 (-2.08%)
F   11.92 (-2.85%)
ACB   11.12 (-4.47%)
DIS   193.88 (-1.84%)
BA   220.73 (-3.75%)
NFLX   542.59 (-1.96%)
BAC   36.23 (-0.41%)
Log in
NASDAQ:SYRS

Syros Pharmaceuticals Stock Forecast, Price & News

$8.97
-0.41 (-4.37 %)
(As of 02/25/2021 02:39 PM ET)
Add
Compare
Today's Range
$8.75
Now: $8.97▼
$9.48
50-Day Range
$9.18
MA: $11.96▼
$14.95
52-Week Range
$4.26
Now: $8.97▼
$15.65
Volume84,756 shs
Average Volume730,745 shs
Market Capitalization$504.09 million
P/E RatioN/A
Dividend YieldN/A
Beta2.01
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subset of patients with acute myeloid leukemia and myelodysplastic syndrome; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was founded in 2011 and is headquartered in Cambridge, Massachusetts.
Syros Pharmaceuticals logo

Headlines

Syros to Report Fourth Quarter and Full Year 2020 Financial Results on Thursday, March 4, 2021
February 25, 2021 |  finance.yahoo.com
What Kind Of Investors Own Most Of Syros Pharmaceuticals, Inc. (NASDAQ:SYRS)?
January 26, 2021 |  finance.yahoo.com
Syros Announces Proposed Offering of Common Stock
January 19, 2021 |  finance.yahoo.com
CORRECTING and REPLACING Syros to Present at 39th Annual J.P. Morgan Healthcare Conference
January 7, 2021 |  marketwatch.com
Syros to Present at 39th Annual J.P. Morgan Healthcare Conference
January 7, 2021 |  finance.yahoo.com
Syros Pharmaceuticals Inc
December 23, 2020 |  bloomberg.com
Is SYRS A Good Stock To Buy Now?
December 14, 2020 |  finance.yahoo.com
Syros Closes $90.5 Million Strategic Financing
December 8, 2020 |  finance.yahoo.com
Syros Acquires Clinical-Stage Drug Candidate for Acute Promyelocytic Leukemia, Expanding Its Pipeline of Targeted Therapies for Hematologic Malignancies
December 5, 2020 |  finance.yahoo.com
Syros Presents New Data From Phase 2 Clinical Trial of SY-1425 and Announces Plans to Initiate Registration-Enabling Trial in MDS and Randomized Phase 2 Trial in AML
December 5, 2020 |  finance.yahoo.com
Syros Pharmaceuticals to Present at Piper Sandler 32nd Annual Virtual Healthcare Conference
November 16, 2020 |  finance.yahoo.com
Earnings Update: Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Just Reported And Analysts Are Boosting Their Estimates
November 9, 2020 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SYRS
Previous Symbol
CUSIPN/A
CIK1556263
Webwww.syros.com
Phone617-744-1340
Employees83
Year FoundedN/A

Debt

Debt-to-Equity Ratio0.44
Current Ratio3.51
Quick Ratio3.51

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$1.98 million
Price / Sales254.59
Cash FlowN/A
Price / Cash FlowN/A
Book Value$1.87 per share
Price / Book4.80

Profitability

EPS (Most Recent Fiscal Year)($1.88)
Net Income$-75,440,000.00
Net Margins-743.58%
Return on Equity-111.54%
Return on Assets-49.71%

Miscellaneous

Outstanding Shares56,197,000
Market Cap$504.09 million
Next Earnings Date3/4/2021 (Estimated)
OptionableOptionable

MarketRank™

Overall MarketRank™

1.35 out of 5 stars

Medical Sector

627th out of 1,957 stocks

Pharmaceutical Preparations Industry

316th out of 771 stocks

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
$8.97
-0.41 (-4.37 %)
(As of 02/25/2021 02:39 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SYRS News and Ratings via Email

Sign-up to receive the latest news and ratings for SYRS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Syros Pharmaceuticals (NASDAQ:SYRS) Frequently Asked Questions

Is Syros Pharmaceuticals a buy right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Syros Pharmaceuticals in the last twelve months. There are currently 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Syros Pharmaceuticals stock.
View analyst ratings for Syros Pharmaceuticals or view top-rated stocks.

What stocks does MarketBeat like better than Syros Pharmaceuticals?

Wall Street analysts have given Syros Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Syros Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Syros Pharmaceuticals' next earnings date?

Syros Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, March 4th 2021.
View our earnings forecast for Syros Pharmaceuticals.

How were Syros Pharmaceuticals' earnings last quarter?

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) released its quarterly earnings data on Thursday, November, 5th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.38) by $0.05. The business had revenue of $3.83 million for the quarter, compared to analyst estimates of $2.83 million. Syros Pharmaceuticals had a negative trailing twelve-month return on equity of 111.54% and a negative net margin of 743.58%.
View Syros Pharmaceuticals' earnings history.

How has Syros Pharmaceuticals' stock price been impacted by Coronavirus?

Syros Pharmaceuticals' stock was trading at $5.15 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, SYRS stock has increased by 74.2% and is now trading at $8.97.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for SYRS?

8 analysts have issued 12-month target prices for Syros Pharmaceuticals' shares. Their forecasts range from $13.00 to $20.00. On average, they anticipate Syros Pharmaceuticals' stock price to reach $17.57 in the next year. This suggests a possible upside of 95.9% from the stock's current price.
View analysts' price targets for Syros Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Syros Pharmaceuticals' key executives?

Syros Pharmaceuticals' management team includes the following people:
  • Dr. Nancy A. Simonian, Pres, CEO & Director (Age 60, Pay $897.05k)
  • Dr. Richard A. Young, Scientific Founder, Member of Scientific Advisory Board & Director (Age 67, Pay $165k)
  • Dr. Eric R. Olson, Chief Scientific Officer (Age 63, Pay $638.63k)
  • Dr. David A. Roth, Chief Medical Officer (Age 58, Pay $641.48k)
  • Dr. James E. Bradner, Founder (Age 49)
  • Dr. Nathanael S. Gray Ph.D., Scientific Founder & Member of Scientific Advisory Board
  • Mr. Joseph J. Ferra Jr., CFO & Treasurer (Age 44)
  • Mr. Gerald E. Quirk, Chief Legal & Admin. Officer and Sec. (Age 53)
  • Ms. Naomi Aoki, VP of Corp. Communications & Investor Relations
  • Dr. Christian C. Fritz, Head of Biology

What is Nancy Simonian's approval rating as Syros Pharmaceuticals' CEO?

3 employees have rated Syros Pharmaceuticals CEO Nancy Simonian on Glassdoor.com. Nancy Simonian has an approval rating of 100% among Syros Pharmaceuticals' employees. This puts Nancy Simonian in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Syros Pharmaceuticals' key competitors?

Some companies that are related to Syros Pharmaceuticals include Generation Bio (GBIO), Dicerna Pharmaceuticals (DRNA), Prestige Consumer Healthcare (PBH), Stoke Therapeutics (STOK), Myovant Sciences (MYOV), ADC Therapeutics (ADCT), NGM Biopharmaceuticals (NGM), Praxis Precision Medicines (PRAX), Madrigal Pharmaceuticals (MDGL), Aurinia Pharmaceuticals (AUPH), Zymeworks (ZYME), Seres Therapeutics (MCRB), COMPASS Pathways (CMPS), ImmunoGen (IMGN) and Frequency Therapeutics (FREQ).
View all of SYRS's competitors.

What other stocks do shareholders of Syros Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Syros Pharmaceuticals investors own include Corbus Pharmaceuticals (CRBP), Sangamo Therapeutics (SGMO), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), ImmunoGen (IMGN), VBI Vaccines (VBIV), Amarin (AMRN), Amicus Therapeutics (FOLD), Nektar Therapeutics (NKTR) and Pfizer (PFE).

When did Syros Pharmaceuticals IPO?

(SYRS) raised $60 million in an initial public offering on Thursday, June 30th 2016. The company issued 4,000,000 shares at $14.00-$16.00 per share. Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

What is Syros Pharmaceuticals' stock symbol?

Syros Pharmaceuticals trades on the NASDAQ under the ticker symbol "SYRS."

Who are Syros Pharmaceuticals' major shareholders?

Syros Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Sumitomo Mitsui Trust Holdings Inc. (7.80%), Nikko Asset Management Americas Inc. (7.80%), BlackRock Inc. (5.92%), Samsara BioCapital LLC (3.90%), Orbimed Advisors LLC (2.78%) and Artal Group S.A. (1.33%). Company insiders that own Syros Pharmaceuticals stock include Eric R Olson, Jeremy P Springhorn, Mark J Alles, Richard A Young, Srinivas Akkaraju and Venture Fund Vii LP Arch.
View institutional ownership trends for Syros Pharmaceuticals.

Which major investors are selling Syros Pharmaceuticals stock?

SYRS stock was sold by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Credit Suisse AG, New York State Common Retirement Fund, Northern Trust Corp, Virtus ETF Advisers LLC, ETF Managers Group LLC, State of Wisconsin Investment Board, and Bank of New York Mellon Corp. Company insiders that have sold Syros Pharmaceuticals company stock in the last year include Eric R Olson, Richard A Young, and Srinivas Akkaraju.
View insider buying and selling activity for Syros Pharmaceuticals or view top insider-selling stocks.

Which major investors are buying Syros Pharmaceuticals stock?

SYRS stock was purchased by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, Samsara BioCapital LLC, Artal Group S.A., Nikko Asset Management Americas Inc., Sumitomo Mitsui Trust Holdings Inc., Citigroup Inc., Ikarian Capital LLC, and Renaissance Technologies LLC. Company insiders that have bought Syros Pharmaceuticals stock in the last two years include Jeremy P Springhorn, Mark J Alles, and Srinivas Akkaraju.
View insider buying and selling activity for Syros Pharmaceuticals or or view top insider-buying stocks.

How do I buy shares of Syros Pharmaceuticals?

Shares of SYRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Syros Pharmaceuticals' stock price today?

One share of SYRS stock can currently be purchased for approximately $8.97.

How much money does Syros Pharmaceuticals make?

Syros Pharmaceuticals has a market capitalization of $504.09 million and generates $1.98 million in revenue each year. The company earns $-75,440,000.00 in net income (profit) each year or ($1.88) on an earnings per share basis.

How many employees does Syros Pharmaceuticals have?

Syros Pharmaceuticals employs 83 workers across the globe.

What is Syros Pharmaceuticals' official website?

The official website for Syros Pharmaceuticals is www.syros.com.

Where are Syros Pharmaceuticals' headquarters?

Syros Pharmaceuticals is headquartered at 35 Cambridge Park Drive 4th Floor, CAMBRIDGE MA, 02139.

How can I contact Syros Pharmaceuticals?

Syros Pharmaceuticals' mailing address is 35 Cambridge Park Drive 4th Floor, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-744-1340 or via email at [email protected]


This page was last updated on 2/25/2021 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.